Newsroom | 18121 results
Sorted by: Latest
-
Onchilles Pharma Publishes Landmark ELANE Pathway Study and Advances N17350 Toward the Clinic With New Financing and Leading Clinical Advisor
SAN DIEGO--(BUSINESS WIRE)--Onchilles Pharma Publishes Landmark ELANE Pathway Study and Advances N17350 Toward the Clinic With New Financing and Leading Clinical Advisor...
-
nChroma Bio Presents Preclinical Data Demonstrating Epigenetic Silencing Approach as a Potential Functional Cure for Chronic Hepatitis B at AASLD 2025
BOSTON--(BUSINESS WIRE)--nChroma Bio, a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the limitations of existing therapies, today announced new preclinical data presented at The Liver Meeting® 2025 of the American Association for the Study of Liver Diseases (AASLD). The results, including a Poster of Distinction, highlight the potential of the company’s lead candidate, CRMA-1001, to deliver a functional cure for chronic hepatitis B virus (HBV) through a...
-
Fulgent Reports Third Quarter 2025 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2025. Third Quarter 2025 Results: Revenue of $84.1 million, growing 17% year-over-year GAAP loss of $6.6 million, or ($0.21) per share Non-GAAP income of $4.5 million, or $0.14 per share Adjusted EBI...
-
TwoStep Therapeutics to Present at the 2025 SITC Annual Meeting
SAN CARLOS, Calif.--(BUSINESS WIRE)--TwoStep Therapeutics to Present at the 2025 SITC Annual Meeting...
-
Evinova China and Harbour BioMed Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development
SHANGHAI--(BUSINESS WIRE)--Evinova and Harbour BioMed announced a strategic collaboration in artificial intelligence to build an open ecosystem for AI-driven drug R&D....
-
City of Hope Appoints Leading Lung Cancer Expert Dr. Christine M. Lovly to Head National Thoracic Oncology Program
LOS ANGELES--(BUSINESS WIRE)--City of Hope today announced that Dr. Christine M. Lovly will spearhead the development of its new national thoracic oncology program starting Jan. 1....
-
enGene to Participate in Upcoming Investor Conferences
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference Date: Tuesday, November 11, 2025 Time: 12:30 p.m. ET Stifel 2025 Healthcare Conference Date: Wednesday, November 12, 2025 Time: 2:00 p.m. ET Jefferies Global Healthcare Conference in London Date: Tuesday,...
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 25, 2025, at 4:30 p.m. ET to discuss its financial results for the 2025 fiscal year ended September 30, 2025. Webcast and Conference Call Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two ho...
-
Natera Reports Third Quarter 2025 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2025. Recent Financial Highlights Generated total revenues of $592.2 million in the third quarter of 2025, compared to $439.8 million in the third quarter of 2024, an increase of 34.7%. Product revenues grew 35.3% over the same period. Generated a gross margin percentage2 of 64.9% in the third quarter...
-
Maravai LifeSciences Reports Third Quarter 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2025, together with other business updates. Quarterly Results: Revenue of $41.6 million, Net loss of $(45.1) million, and Adjusted EBITDA of $(10.8) million “We exited the third quarter confident about the future of our business. Cygnus co...